Compare HIPO & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HIPO | ARVN |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 793.2M | 781.0M |
| IPO Year | N/A | 2018 |
| Metric | HIPO | ARVN |
|---|---|---|
| Price | $30.76 | $12.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 23 |
| Target Price | ★ $37.50 | $18.14 |
| AVG Volume (30 Days) | 162.4K | ★ 763.6K |
| Earning Date | 03-05-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 3.71 | N/A |
| Revenue | ★ $450,000,000.00 | $312,300,000.00 |
| Revenue This Year | $28.91 | $11.17 |
| Revenue Next Year | $17.87 | N/A |
| P/E Ratio | $8.16 | ★ N/A |
| Revenue Growth | 34.41 | ★ 93.86 |
| 52 Week Low | $19.92 | $5.90 |
| 52 Week High | $38.98 | $20.38 |
| Indicator | HIPO | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 45.33 | 54.77 |
| Support Level | $29.21 | $11.76 |
| Resistance Level | $32.61 | $12.51 |
| Average True Range (ATR) | 0.91 | 0.52 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 41.76 | 71.94 |
Hippo Holdings Inc is a home insurance group that created a new standard of care and protection for homeowners. It provides insurance for computers, home offices, electronics, appliances, water backup, and service line coverage, among others. It has three reportable segments Services segment earns fees and commission income without assuming underwriting risk or need for reinsurance, Insurance-as-a-Service managed through the company's subsidiary Spinnaker is a platform to support third-party MGAs, and the Hippo Home Insurance Program engaged in homeowners insurance business. It generates the majority of its revenue from the Insurance-as-a-Service segment.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.